Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 1/20 | 0.35 |
| ▸ | RORA | P35398 | 1/20 | 0.35 |
| ▸ | RORC | P51449 | 1/20 | 0.35 |
| ▸ | RORB | Q92753 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.33 |
| ▸ | AHR | P35869 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL861977 | 0.93 | PGR (0.35) | PGRRORARORCRORBMEN1 | |
| SCHEMBL861219 | 0.91 | RORA (0.34) | PGRRORARORCRORBMEN1 | |
| SCHEMBL861600 | 0.90 | PGR (0.33) | PGRRORARORCRORBMEN1 | |
| SCHEMBL13286933 | 0.87 | MAPT (0.33) | KMT2ALMNAKDM4E | |
| SCHEMBL840965 | 0.87 | LMNA (0.34) | LMNA | |
| SCHEMBL29631725 | 0.85 | PGR (0.38) | PGRRORARORCRORBMEN1 | |
| SCHEMBL841646 | 0.85 | PGR (0.38) | PGRRORARORCRORBMEN1 | |
| SCHEMBL21917530 | 0.84 | IKBKB (0.33) | LMNA | |
| SCHEMBL29911566 | 0.84 | PGR (0.37) | PGRRORARORCRORBMEN1 | |
| SCHEMBL29801927 | 0.84 | PGR (0.37) | PGRRORARORCRORBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150311455-A1 | Method Of Forming Metal Complex Compound, And Organic Electroluminescence Device | UDC IRELAND LTD (IE) | 2015-10-29 | — | — | US | disclosed |
| US-20150311455-A1 | Method Of Forming Metal Complex Compound, And Organic Electroluminescence Device | UDC IRELAND LTD (IE) | 2015-10-29 | — | — | US | disclosed |
| US-9062084-B2 | Method of forming metal complex compound, and organic electroluminescence device | UDC Ireland (IE) | 2015-06-23 | — | — | US | disclosed |
| US-8142909-B2 | Blue phosphorescent imidazophenanthridine materials | UNIVERSAL DISPLAY CORPORATION (US) | 2012-03-27 | — | — | US | disclosed |
| US-8142909-B2 | Blue phosphorescent imidazophenanthridine materials | UNIVERSAL DISPLAY CORPORATION (US) | 2012-03-27 | — | — | US | disclosed |
| US-8142909-B2 | Blue phosphorescent imidazophenanthridine materials | UNIVERSAL DISPLAY CORPORATION (US) | 2012-03-27 | — | — | US | disclosed |
| US-20110050093-A1 | METHOD OF FORMING METAL COMPLEX COMPOUND, AND ORGANIC ELECTROLUMINESCENCE DEVICE | FUJIFILM CORPORATION (JP) | 2011-03-03 | — | — | US | disclosed |
| WO-2008156879-A1 | BLUE PHOSPHORESCENT IMIDAZOPHENANTHRIDINE MATERIALS | UNIVERSAL DISPLAY CORPORATION (US) | 2008-12-24 | — | — | WO | disclosed |
| WO-2008156879-A1 | BLUE PHOSPHORESCENT IMIDAZOPHENANTHRIDINE MATERIALS | UNIVERSAL DISPLAY CORPORATION (US) | 2008-12-24 | — | — | WO | disclosed |
| US-20080297033-A1 | BLUE PHOSPHORESCENT IMIDAZOPHENANTHRIDINE MATERIALS | UNIVERSAL DISPLAY CORPORATION | 2008-12-04 | — | — | US | disclosed |
| US-20080297033-A1 | BLUE PHOSPHORESCENT IMIDAZOPHENANTHRIDINE MATERIALS | UNIVERSAL DISPLAY CORPORATION | 2008-12-04 | — | — | US | disclosed |
| US-20080297033-A1 | BLUE PHOSPHORESCENT IMIDAZOPHENANTHRIDINE MATERIALS | UNIVERSAL DISPLAY CORPORATION | 2008-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110050093-A1 | METHOD OF FORMING METAL COMPLEX COMPOUND, AND ORGANIC ELECTROLUMINESCENCE DEVICE | ZFR, PORCN, OR10J3 | PGR 3202/4885RORA 2945/4885RORC 2265/4885 |
| US-20150311455-A1 | Method Of Forming Metal Complex Compound, And Organic Electroluminescence Device | ZFR, PORCN, OR10J3 | PGR 3202/4885RORA 2945/4885RORC 2265/4885 |
| US-20080297033-A1 | BLUE PHOSPHORESCENT IMIDAZOPHENANTHRIDINE MATERIALS | IK, CRY1, MAP1LC3C | PGR 3621/4885RORA 2304/4885RORC 1702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.